Logo
x

Search

Subscribe Now

Hansa Biopharma

Hansa Biopharma Reports the Results from the NICE-01 Clinical Evaluation of HNSA-5487

Hansa Biopharma Reports the Results from the NICE-01 Clinical Evaluation of HNSA-5487

  • October 7, 2024
Hansa Biopharma Reports First Patient Treatment of Imlifidase in P-II Study for ANCA-Associated Vasculitis

Hansa Biopharma Reports First Patient Treatment of Imlifidase in P-II Study for ANCA-Associated Vasculitis

  • July 19, 2023
Hansa Biopharma Receives Positive Reimbursement Decision for Idefirix (imlifidase) in the Czech Republic

Hansa Biopharma Receives Positive Reimbursement Decision for Idefirix (imlifidase) in the Czech Republic

  • January 2, 2023
Hansa Biopharma's Idefirix (imlifidase) Receives NICE Recommendation as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma's Idefirix (imlifidase) Receives NICE Recommendation as Desensitization Treatment for Highly Sensitized Kidney Tra...

  • June 16, 2022
Hansa Biopharma Signs an Agreement with AskBio to Evaluate Imlifidase as Pre-Treatment in Pompe Disease

Hansa Biopharma Signs an Agreement with AskBio to Evaluate Imlifidase as Pre-Treatment in Pompe Disease

  • January 4, 2022
Hansa Biopharma Reports First Patient Enrollment in (ConfIdeS) Trial of Imlifidase for the Treatment of Patients with Kidney Transplant

Hansa Biopharma Reports First Patient Enrollment in (ConfIdeS) Trial of Imlifidase for the Treatment of Patients with Kidney Trans...

  • December 29, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.